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Abstract
Objective:  Fructooligosacharides  and  galactooligosacharides  soften  fecal  bolus  and  increase
frequency  of  depositions  when  added  to  infant  formula.  This  study  aimed  to  determine  the
effects of  galactooligosaccharide  in  pediatric  patients  with  chronic  constipation.
Methods:  From  2010  to  2012,  20  constipated  patients  (4--16  years  of  age)  attended  to  at
a primary  healthcare  unit  were  enrolled  in  a  double-blinded,  placebo-controlled  crossover
trial. Eleven  children  ingested  galactooligosaccharide  (1.7  g)  for  30  days,  followed  by  a  15-
day washout  period,  and  a  30-day  period  of  placebo  (maltodextrin).  Nine  patients  ingested
maltodextrin  for  30  days,  followed  by  15-day  washout  period,  and  galactooligosaccharide
(1.7 g)  for  30  days.  Constipation  symptoms  were  considered  as  primary  outcomes:  bowel  move-
ments/week,  straining  during  defecation,  and  stool  consistency.  Outcome  symptoms  were
ranked according  to  a  numerical  scale  elaborated  for  this  study.  Data  were  recorded  at  base-
line, and  on  days  15  and  30  of  each  30-day  crossover  period.  Repeated-measures  analysis  of
variance (ANOVA)  was  used  to  analyze  symptoms  along  time.
Results:  At  baseline,  there  was  no  signiﬁcant  difference  in  symptoms  severity  between  groups
(p =  0.45).  Galactooligosaccharide  ingestion  was  related  to  increase  of  the  bowel  movement
frequency,  p  <  0.0001;  relief  of  defecation  straining,  p  <  0.0001;  and  decrease  in  stool  con-
sistency, p  =  0.0014,  compared  to  placebo  ingestion.  Patients  reported  no  side  effects  from
galactooligosaccharide.
 Please cite this article as: Beleli CA, Antonio MA, dos Santos R, Pastore GM, Lomazi EA. Effect of 4′galactooligosaccharide on constipation
symptoms. J Pediatr (Rio J). 2015;91;567--73.
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Conclusion:  Galactooligosaccharide  was  effective  at  improving  clinical  symptoms  in  this  group
of constipated  children.
©  2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Efeito  do  galactooligosacarídeo  sobre  os  sintomas  de  constipac¸ão
Resumo
Objetivo:  A  adic¸ão  de  frutooligosacarídeos  e  galactooligosacarídeos  a  fórmulas  infantis  pode
diminuir a  consistência  fecal  e  aumentar  a  frequência  das  evacuac¸ões.  O  objetivo  do  presente
estudo foi  determinar  o  efeito  do  galactooligosacarídeo  em  crianc¸as  com  constipac¸ão  crônica.
Métodos: Entre  2010  e  2012,  20  pacientes  constipados  (4-16  anos),  atendidos  numa  unidade
básica de  saúde,  completaram  ensaio  clínico  duplo  cego,  placebo-controlado  e  de  delinea-
mento crossover.  Onze  pacientes  receberam  galactooligosacarídeo  (1,7  g)  por  30  dias,  seguidos
por 15  dias  de  washout,  e,  após,  placebo  (maltodextrina)  por  30  dias;  outros  nove  pacientes
receberam  placebo  30  dias,  seguidos  de  15  dias  de  washout  e  30  dias  de  galactooligosacarídeo
(1,7 g).  Os  desfechos  primários  foram  frequência  semanal  de  evacuac¸ões,  esforc¸o  evacuatório  e
consistência  fecal,  classiﬁcada  por  escala  numérica  elaborada  para  esse  estudo  e  compilada  no
primeiro, 150 e  300 dias  de  cada  período  de  crossover.  Análise  estatística  foi  feita  por  método
de análise  de  variância  (ANOVA)  para  medidas  repetidas.
Resultados:  Intensidade  dos  sintomas  nos  grupos  foi  semelhante  no  início  do  estudo  (p  =  0,45).
Durante a  ingestão  de  galactooligosacarídeo  constatou-se  maior  frequência  de  evacuac¸ões,
p <  0,0001,  menor  diﬁculdade  evacuatória,  p  <  0,0001  e  diminuic¸ão  da  consistência  fecal,
p =  0,0014.  Efeitos  colaterais  não  foram  referidos  durante  a  ingestão  do  prebiótico.
Conclusão:  Durante  a  ingestão  de  galactooligosacarídeo  os  sintomas  clínicos  da  constipac¸ão  em
crianc¸as e  adolescentes  foram  signiﬁcantemente  aliviados.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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ata  from  the  last  decades  have  indicated  childhood  con-
tipation  as  a  common  problem  worldwide.  Its  reported
revalence  has  varied  from  0.7%  to  30%;  in  addition,  in
ecent  years,  the  number  of  patients  has  grown  signiﬁcantly
n  western  world.1,2 Different  therapeutics  have  been  rec-
mmended  for  constipation  management,  including  stool
ubricants,  dietary  ﬁber  supplementation,  laxatives,  proki-
etics,  and  functional  foods.  Osmotic  laxatives  and  dietary
bers  are  the  most  widely  used  therapeutic  tools;  however,
here  are  very  few  evidence-based  studies  to  support  any
reatment  recommendations  for  constipation  in  pediatric
atients.3,4
Functional  foods  containing  probiotics  or  prebiotics
ave  been  identiﬁed  as  useful  for  regulating  bowel  habits
n  children.5 A  multicenter  controlled  trial  showed  that
onsumption  of  fermented  dairy  products  containing  Biﬁ-
obacterium  lactis  was  associated  to  increase  in  stool
requency  in  children  with  constipation  and  stool  frequency
3  times/week.6
Concerning  the  effects  of  prebiotics  on  laxation,  studies
onducted  in  pediatric  patients  have  included  predomi-
antly  infants  fed  exclusively  on  milk  formulas.  Ingestion
f  prebiotics  was  proposed  to  be  effective  for  treating
onstipation,  since  consumption  of  fructooligosaccharides
nd  galactooligosaccharides  added  to  infant  formula  has
n
eeen  shown  to  increase  fecal  bolus  and  the  frequency  of
epositions.7--10
The  rationale  of  prebiotics’  therapeutic  effects  on  con-
tipation  is  based  on  the  fact  that  4′galactooligosaccharide
GOS)  affects  the  host  health  by  stimulating  the  growth
nd/or  activity  of  colonic  biﬁdobacteria.11 Biﬁdobacte-
ia,  mainly  Lactobacillus  acidophillus  or  Biﬁdobacterium
iﬁdum,  act  by  fermenting  carbohydrates,  producing  short
hain  fatty  acids  (SCFAs),  the  major  anion  on  the  large  intes-
ine;  SCFAs  are  able  to  increase  colonic  blood  ﬂow  and
uscular  activity,  enhancing  fecal  wet  weight  and  thus  pro-
oting  laxation.12,13
The  current  study  was  aimed  at  evaluating  the  effective-
ess  of  the  prebiotic  GOS  in  the  treatment  of  constipation
n  children  and  adolescents.
ethods
esign:  An  interventional,  non-randomized,  double-blinded,
lacebo-controlled,  crossover  assignment  study  was  con-
ucted  from  June  8,  2010  to  March  25,  2012.
Setting:  A  primary  healthcare  unit  managed  by  medical
chool  staff.Patients:  Subjects  aged  4--16  years  old  who  sponta-
eously  sought  medical  care  and,  when  eligible  after  initial
xamination,  were  invited  to  participate  in  the  study.
Galactooligosaccharide  on  constipation  569
Assessed for eligibility (n = 23) 
Excluded (n = 1) 
♦Not meeting inclusion criteria (n = 0) 
♦Declined to participate (n = 0) 
♦Other  rea sons  (n = 1 )
Analysed (n = 11) 
Lost to follow-up (give reasons) (n = 0) 
Discontinued intervention (give reasons) (n = 0)
Allocated to intervention (n = 11) 
♦ Received allocated intervention (n = 11)
Discontinued intervention (declined to 
participate) (n = 2) 
Lost to follow-up (n = 0) 
Allocated to intervention (n = 11) 
♦ Received allocated intervention (n = 11)
Analysed (n = 9) 
Analysis
Follow-Up
Enrollment 
Parallel-group controlled trial with a 
1:1 allocation ratioAllocation 
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nFigure  1  Study  ﬂowchart  according  to  the  Con
Eligibility  criteria
Inclusion  criterion:  Diagnosis  of  constipation  based  on  the
Rome  III  criteria  for  functional  disorders.14 Furthermore,  in
order  to  exclude  lactose  intolerance,  to  be  enrolled  patients
were  required  to  report  a  daily  ingestion  of  at  least  250  mL  of
cow’s  milk  without  referring  symptoms,  and  they  were  asked
speciﬁcally  about  pain,  cramping,  diarrhea,  or  ﬂatulence
after  milk  ingestion.
Non-inclusion  criterion:  Patients  with  other  comorbid
conditions,  those  already  under  treatment  for  constipation,
and  those  who  used  antibiotics  or  probiotics  for  the  last  6
months.
Study  products
Test  product:  The  prebiotic  GOS  was  produced  from  lactose
through  the  action  of  -galactosidase  enzymes,  produced  by
the  microorganism  Scopulariopsis  sp.15 A  daily  6 mL  volume
of  prescribed  maltodextrin  solution  (placebo)  and  GOS  was
ingested  in  the  morning.  In  the  GOS  mixture,  a  volume  of
6  mL  containing  1.7  g  GOS  was  used.  Parents/guardians  and
participants  were  informed  of  possible  GOS  ingestion  side
effects,  such  as  abdominal  distention,  ﬂatulence,  abdominal
cramping,  and  diarrhea.
t
c
aated  Standards  of  Reporting  Trials  statement.30
Control:  The  placebo  consisted  of  a  maltodextrin  solu-
ion.
linding
he  two  treatments,  prebiotic  GOS  and  placebo,  were  iden-
ical  in  viscidity,  color,  smell,  taste,  and  packaging.  All
esearch  staff  and  patients  involved  were  unaware  of  the
reatment  administered  to  the  patient.
rder  of  patients  inclusion  in  study  and  ﬂow
iagram
he  trial  consisted  of  a  two-sequence,  two-period,  two-
reatment  crossover  design.  Each  crossover  period  lasted
0  days,  separated  by  15  days  as  the  washout  period.  The
equence  of  GOS  or  placebo  ingestion  deﬁned  by  the  ﬁrst
atient  enrolled  in  the  study  was  chosen  by  lot.  The  order  of
ngestion  in  the  followed  patients  was  systematically  alter-
ate.  Fig.  1  shows  a  study  ﬂowchart.16Clinical  data  collection  related  to  constipation  symp-
oms,  substance  delivery  (GOS  or  placebo),  and  compliance
ontrol  were  achieved  during  home  visits  every  two  weeks:
t  baseline,  day  15,  and  day  30,  in  both  30-day  study  periods.
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ompliance  with  substances  was  measured  by  the  return  of
reviously  used  ﬂasks.
ample  size  calculation
ata  from  10  subjects  who  ﬁrst  completed  the  study  were
nalyzed  by  ANOVA  to  calculate  sample  size.17 SAS  soft-
are  for  sample  size  calculation  was  used,  v.  9.2  of  the
AS  System  for  Windows  (SAS  Institute  Inc.  Cary,  NC,  USA).
tatistical  analysis  using  analysis  of  variance  (ANOVA)  for
epeated  measures  was  applied.  ANOVA  was  used  to  analyze
omparative  treatments,  considering  the  difference  in  out-
omes.  Power  analysis  was  applied  in  the  context  of  ANOVA
y  assuming  a  two-sequence,  two-period,  two-treatment
rossover  design,  effect  size  in  the  population,  sample  size,
nd  signiﬁcance  level.  A  statistically  signiﬁcant  effect  in
NOVA  was  monitored  with  follow-up  tests,  in  order  to  assess
hich  variable  was  different  between  groups.  Follow-up
ests  were  performed  post  hoc. SAS  software  ‘‘fpower’’
as  then  used  to  calculate  sample  size  after  specifying  the
ower  of  study  at  90%  and  alpha  =  0.05.  Such  analysis  showed
hat  using  a  power  analysis  of  90%,  nine  subjects  would  be
equired  in  each  group.
Further  dietary  ﬁber  supplementation  was  not  allowed
ntil  completion  of  the  trial.  For  those  patients  who  refused
o  participate  in  the  study  or  those  who  completed  the  trial,
ietary  ﬁber  was  prescribed.
utcomes
hree  symptoms  were  considered  as  primary  outcomes:
owel  movements  per  week,  fecal  consistency  and  strain-
ng/pain  during  fecal  passage.  These  symptoms  were  ranked
ccording  to  numerical  values.  Bowel  movements  frequency
as  ranked  from  1  to  3,  as  follows:  1  =  greater  than  three
imes  per  week;  2  =  one  to  two  times  per  week;  and  3  =  less
han  once  per  week.  Intensity  of  straining/pain  during  stool
assage  ranged  from  1  to  3  (1  =  no  discomfort  or  pain,
 =  episodic  pain  and/or  discomfort,  and  3  =  pain  and/or
iscomfort  during  every  stool  passage).  Fecal  consistency
as  deﬁned  according  to  a  photographic  scale18 and  var-
ed  from  3  to  0 (3  =  hard,  separate  lumps,  2  =  banana  with
eep  cracks,  1  =  banana  with  superﬁcial  cracks,  and  0  =  soft
anana/separate  soft  pieces/ﬂuffy  pieces).  The  sum  of  val-
es  ranged  from  2  to  9  and  was  considered  a  clinical  score
haracterizing  symptom  intensity.  The  physical  evaluation
nd  patient  scores  were  compiled  during  the  baseline  inter-
iew,  and  on  day  15  and  30  in  each  period.
tatistical  analysis
escriptive  analyses  were  performed,  including  measures
f  central  tendency  and  dispersion  for  numerical  variables.
t  baseline,  clinical  and  demographic  data  were  compared
Mann--Whitney  test).
GOS  effect  was  determined  according  to  a  two-period,
wo-treatment  crossover  assignment:  GOS  and  placebo.  The
olmogorov--Smirnov  test  was  performed  to  test  normality
f  data,  rejecting  the  null  hypothesis  of  normality.  For  statis-
ical  analysis,  ANOVA  was  used  for  repeated  measurements
w
a
s
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ith  rank-transformation  (ANOVA  on  ranks).  Ranking  is  a  pro-
edure  used  to  transform  data  that  violate  the  assumptions
f  normality.  ANOVA  on  ranks  signiﬁes  that  a  standard  anal-
sis  of  variance  has  been  calculated  on  rank-transformed
ata.  The  signiﬁcance  level  adopted  for  statistical  tests  was
%.
The  study  was  approved  by  the  Ethics  Committee  of
he  institution,  No.  366/2009,  CAAE:  0280.0.146.000-09.  All
articipants  and/or  parents/guardians  signed  an  informed
onsent.  The  study  was  reviewed  and  published  on  the  site
linicalTrials.gov,  identiﬁer  number:  NCT02183766.
esults
wenty-three  patients  were  initially  included,  but  three
atients  were  lost  to  follow-up  due  to  a  change  of  address
ithout  any  previous  communication.  Twenty  children  and
dolescents  aged  4--16  years  (mean  8.8  ±  4.1  SD)  were
ncluded.  Twelve  children  were  female.  After  unblinding,
t  was  observed  that  11  patients  received  the  sequence  of
OS  to  placebo  and  nine  patients  received  the  sequence
f  placebo  to  GOS.  None  of  the  patients  refused  treatment
r  had  a  low  acceptance  of  medication.  At  the  baseline
nterview,  all  patients  reported  fewer  than  three  bowel
ovements  per  week  or  hard  stool  consistency.
Since  patients  were  systematically  allocated  to  groups
ccording  to  consecutive  ﬁrst  health  care  visit,  the  effect
f  allocation  (order  of  product  ingestion)  was  calculated
y  ANOVA  for  repeated  measures;  there  was  no  difference
etween  the  groups’  scores  determined  by  group  allocation,
 = 0.9427.
linical  scores  over  time
able  1  shows  demographic  clinical  data  from  20  patients
ho  completed  the  trial.  Tables  2  and  3  show  the  distribution
f  clinical  scores,  considering  GOS  effect  and  time  effect,
espectively,  i.e., clinical  scores  over  time.  Mean  clinical
cores  decreased  signiﬁcantly  during  GOS  ingestion  in  both
roups  (Table  2).  Mean  clinical  scores  over  time  showed  that
he  effect  of  GOS  lasted  throughout  its  ingestion,  since  the
ashout  period  stopped  the  effect  of  GOS.  There  was  no
roup/time  interaction  (Table  3).
iscussion
he  prebiotic  GOS  ingested  by  constipated  children  was
ffective  at  increasing  bowel  movement  frequency,  reliev-
ng  pain  or  discomfort  during  stool  passage,  and  softening
tool  consistency.  No  adverse  effects  were  reported.
GOS  has  been  shown  to  be  effective  for  improving  consti-
ation  in  elderly  subjects,  pregnant  women,  and  infants.19,20
evertheless,  to  the  best  of  the  authors’  knowledge,  no  clin-
cal  trials  have  studied  GOS  effects  in  constipated  children  or
dolescents.  Studies  including  schoolchildren  or  adolescents
hile  managed  in  outpatient  clinics  are  highly  burdensome
nd  require  strict  control  on  drug  adherence.  In  the  present
tudy,  it  took  considerable  effort  to  measure  adherence  and
ymptoms  by  frequent  home  visits.
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Table  1  Baseline  demographics  and  clinical  characteristics.
GOS  →  Placebo  Group  1  (n  =  11)  Placebo  →  GOS  Group  2  (n  =  9)  p-Valuea
Variable
Sex,  M:F 4:7  4:5  NS
Age, (years)  (mean  ±  SD)  8.7  ±  4.8  8.8  ±  3.5  NS
Age at  early  symptoms,  (years,  mean  ±  SD)  5  ±  4.7  3.8  ±  2.4  NS
Constipation  started  on  1st  year  of  life  3/11  1/9  NS
Duration of  constipation  (years)  3.8  ±  0.7  5.4  ±  3.45  NS
Bowel movements/week  (Baseline)  1.5  ±  0.5  1.7  ±  0.7  NS
Stool consistencyb
Mean  ±  SD  2.8  ±  0.2  2.6  ±  0.2  0.07
Median (min-max) 3  (1--2)  2.5  (2.5--3)
Baseline scorec 6.5  ±  1 6.1  ±  1.4 0.45
Score during  GOS  4.6  ±  1.2  4.3  ±  1  0.70
Score during  placebo  5.8  ±  1.1  6  ±  1.3  0.65
Clinical score is presented as mean ± SD.
GOS, galactooligosaccharide.
a Mann--Whitney test.
b Stool consistency classiﬁcation: 3 = hard; 2 = banana with deep cracks; 1 = banana with superﬁcial cracks, zero = soft banana/separate
soft pieces/ﬂuffy pieces.
c Clinical score included bowel frequency, fecal consistency, and defecation discomfort, and ranged from 9 (greatest severity) to 2 (no
symptoms).
Table  2  Clinical  scores  based  on  bowel  frequency,  fecal  consistency,  and  defecation  discomfort.
Period  1
Mean  ±  SD
Period  2
Mean  ±  SD
Baseline  Day  15  Day  30  Baseline  Day  15  Day  30
Group  1  (initial  sequence:
GOS  →  placebo)  (n  =  11)
6.82  ±  1.47  3.73  ±  1.68  3.09  ±  1.64  5.55  ±  1.57  6  ±  1.67  6.18  ±  1.72
Group 2  (initial  sequence:
placebo  →  GOS)  (n  =  9)
6.11  ±  1.45 6.11  ±  1.36 5.78  ±  1.39  6.11  ±  1.36  3.67  ±  1.22  3.11  ±  1.36
p-Valuea 0.1739  0.0004  <0.0001  0.1237  <0.0001  <0.0001
GOS, galactooligosaccharide.
a ANOVA.
Table  3  Clinical  data  and  time  effect  (clinical  data  over  time)  using  analysis  of  variance  (ANOVA).
Score/group  Period  1
Mean  ±  SD
p-Value
Time
effect
Period  2
Mean  ±  SD
p-Value
Time
effect
Baseline  Day  15  Day  30  Baseline  Day  15  Day  30
Group  1
GOS  →  Placebo
(n  =  11)
6.82  ±  1.47  3.73  ±  1.68  3.09  ±  1.64  <0.0001a 5.55  ±  1.57  6  ±  1.67  6  ±  1.72  <0.0001b
Group  2
Placebo  →  GOS
(n  =  9)
6.11  ±  1.45  6.11  ±  1.36  5.78  ±  1.39  0.4493  6.11  ±  1.36  3.67  ±  1.22  3.11  ±  1.36  0.0105b
Clinical score ranged from 9 (greatest severity) to 2 (no symptoms).
 15 of
 15 anGOS, galactooligosaccharide.
a p-Value refers to clinical score values at baseline time vs. day
b p-Value refers to clinical score values at baseline time vs. dayThe  main  symptoms  of  constipated  children  seek-
ing  Brazilian  primary  health  care  settings  refer  to  hard
stools  and  large  intervals  between  bowel  movements.
Less  than  15%  of  patients  reported  fecal  retentive
i
e
a
s trial.
d at baseline time vs. day 30 of trial.ncontinence.21 Primary  care  treatment  prescribed  for
arly  constipation  symptoms  in  children  varies  consider-
bly,  and  usually  less  than  50%  of  these  patients  are
uccessfully  treated.22 GOS  ingestion  promoted  relief  of
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omplaints  during  its  ingestion,  regardless  other  adjuvant
ecommendation.
In  present  study,  mean  duration  was  from  3  to  5  years.  It
s  likely  that  most  patients  had  already  been  treated  but  did
ot  continue  with  therapy.  No  patient  referred  symptoms  of
etentive  fecal  incontinence  or  had  fecal  retention  palpable
n  abdomen  or  identiﬁed  by  rectal  examination.  It  appears
hat  the  patients  have  mild  constipation,  responsive  to  oral
axatives  and  with  no  complications.  Such  a  clinical  picture
s  found  commonly  in  constipated  children  treated  in  pri-
ary  healthcare  centers.  These  data  show  that  as  a  group,
hildren  and  adolescents  improve  while  using  GOS,  and  no
hanges  in  symptom  were  recorded  with  placebo.  No  other
ort  of  therapy  was  recommended  besides  strict  adherence
o  the  products.
In  spite  of  a  paucity  of  data  providing  conclusive  evidence
o  support  the  current  recommendations  of  ﬁber  intake  for
onstipated  pediatric  patients,  pediatric  clinical  trials  have
hown  that  dietary  ﬁber  increases  the  frequency  of  defeca-
ion  and  stool  softness.23 Diet  modiﬁcation  to  increase  ﬁber
onsumption  is  considered  an  important  component  in  the
anagement  of  constipation.  Dietary  ﬁber  supplementation
as  not  prescribed  during  this  trial,  in  order  to  better  evalu-
te  the  isolated  GOS  effect  on  fecal  characteristics.  Dietary
ber  was  prescribed  to  subjects  who  declined  to  participate
n  the  study  or  to  those  who  had  completed  the  trial.
Broad  age  range  and  sample  size  should  be  discussed
s  limitations  of  the  present  study.  The  pathogenesis  of
on-organic  constipation  is  closely  related  to  stool  toilet-
ng  refusal  caused  by  pain  during  stool  passage,  generally
ccurring  during  the  toilet-training  period.  Such  patients
sually  have  a  previous  history  of  hard  feces,  and  infrequent
nd  painful  evacuation  often  accompanied  by  screaming
nd  stool-holding  maneuvers.  When  symptoms  are  not
ddressed,  the  condition  progresses  until  a  diagnosis  is
ade.  In  around  50%  of  children,  a  long-term  outcome  can
e  observed,  and  25%  of  children  with  functional  consti-
ation  continue  to  experience  symptoms  into  adulthood.24
ong-term  constipation  is  associated  with  fecal  impaction,
etentive  incontinence,  and  megarectum.  Irrespective  of
omplications  and  age,  good  clinical  outcomes  were  deﬁned
s  at  least  three  bowel  movements  per  week  for  at  least  4
eeks,  with  no  more  than  two  episodes  of  fecal  incontinence
er  month,  irrespective  of  laxative  use.24 Considering  patho-
enesis  context,  it  must  be  pointed  out  that  despite  age
ariability,  the  included  subjects  were  very  similar  in  their
onstipation  characteristics,  with  no  subjects  presenting
igns  of  complications  such  as  fecal  impaction  and  require-
ent  of  aggressive  laxatives.  In  respect  to  the  small  sample
ssue,  the  crossover  design  was  chosen  because  this  design
nabled  researchers  to  make  comparisons  between  small
amples;  the  sample  size  was  primarily  deﬁned  as  sufﬁcient
y  statistical  analysis.  Accepting  these  considerations,  it  is
ossible  to  conclude  that  the  present  results  are  true  for
atients  with  mild  symptoms.
In  studies  conducted  to  evaluate  prebiotic  effects  on
nfant  constipation,  treatment  duration  ranged  from  21  days
o  8  weeks  for  symptom  evaluation.  A  4-week  period  was
roposed  based  on  such  studies.25--27
The  ﬁxed  GOS  dosage  was  chosen  to  provide  an  ade-
uate  balance  between  efﬁcacy  and  tolerance,  according
o  results  from  adult  trials.  It  was  not  possible  to  examineBeleli  CA  et  al.
iﬁdogenic  effect  on  microbiota  or  the  increased  produc-
ion  of  fecal  SCFAs.  According  to  the  literature,  the  addition
f  12  g/day  of  GOS  was  shown  to  be  effective  and  well-
olerated,  resulting  in  increased  fecal  biﬁdobacteria  in
ealthy  individuals.28,29 It  was  shown  that  the  estimated
afe  adult  dose  ranging  from  0.3  to  0.4  g/kg/day  and  2.5  g
OS  is  sufﬁcient  to  induce  a  biﬁdogenic  effect.30 An  exces-
ive  amount  of  GOS  could  promote  adverse  osmotic  effects
eading  to  osmotic  diarrhea,  symptoms  not  referred  by  the
resent  patients  during  GOS  ingestion.
This  pilot  study  showed  that  GOS  improves  clinical  consti-
ation  symptoms  and  may  represent  a  supportive  measure
n  the  treatment  of  constipation.  To  conﬁrm  these  ﬁndings,
 larger,  randomized,  placebo-controlled  trial  is  required.
unding
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